GlassScriptPhysician profile
Shadi N Daoud
NPI 1699739151
$26,822.53
in general payments reported to CMS, 2019-2025
40 companies · $1,820 in 2025
The $1,820 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,666 · 2021: $3,550 · 2022: $1,804 · 2023: $1,438 · 2024: $1,837 · 2025: $1,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,095.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13,220.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,730.83 | 2020-2024 | Farxiga, Wainua |
| Abbott Laboratories | $1,876.62 | 2019-2025 | Aveir, Mitraclip, 2nd Gen Centrimag Primary Console |
| E.R. Squibb & Sons, L.L.C. | $934.39 | 2020-2025 | Camzyos, Eliquis |
| Amgen INC. | $610.99 | 2020-2025 | Repatha, Repatha |
| Abiomed | $598.79 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $533.29 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $511.14 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $425.97 | 2021-2025 | |
| Philips North America LLC | $421.73 | 2020-2025 | (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Medtronic Vascular, INC. | $404.36 | 2019-2020 | |
| Edwards Lifesciences Corporation | $303.55 | 2020-2025 | Evoque |
| Boston Scientific Corporation | $265.09 | 2019-2025 | Watchman Flx |
| Merck Sharp & Dohme LLC | $243.77 | 2021-2025 | Verquvo, Winrevair |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.59 | 2023-2024 | Lifevest |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $167.15 | 2019-2023 | Xarelto |
| Biosense Webster, INC. | $163.17 | 2021-2024 | Carto 3, Nuvision Ice Catheter, Qdot Micro Catheter |
| Medtronic, INC. | $139.25 | 2021 | |
| Bridgebio Pharma, INC. | $110.60 | 2025 | Attruby |
| Itamar Medical INC | $107.93 | 2023-2025 | Watchpatone |
| Kiniksa Pharmaceuticals, LTD. | $96.97 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $88.38 | 2025 | Amvuttra |
| Lantheus Medical Imaging, INC. | $82.55 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $69.75 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $55.41 | 2024 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $54.45 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $52.63 | 2024 | |
| Heartflow, INC. | $51.19 | 2025 | |
| Cvrx, INC. | $50.59 | 2023-2025 | Barostim Neo System |
| Atricure, INC. | $44.55 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $29.60 | 2022 | |
| Teleflex LLC | $26.92 | 2023 | Manta |
| Actelion Pharmaceuticals US, INC. | $24.23 | 2024 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $21.10 | 2025 | Nexletol |
| Irhythm Technologies, INC. | $20.88 | 2022 | |
| Shockwave Medical, INC | $20.45 | 2021 | |
| Lilly USA, LLC | $19.22 | 2025 | Mounjaro, Zepbound |
| Vifor Pharma, INC. | $17.91 | 2021 | |
| Baxter Healthcare | $17.61 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Sanofi-Aventis U.S. LLC | $16.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadi Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.